Page last updated: 2024-08-24

plerixafor and Cryptogenic Fibrosing Alveolitis

plerixafor has been researched along with Cryptogenic Fibrosing Alveolitis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, X; Guo, X; Lian, H; Rosas, I; Wang, L; Wang, N; Xia, C; Xu, K; Yang, J; Yu, G; Zhao, W1
Chen, G; Ding, L; Li, Z; Oupicky, D; Sun, M; Wang, Y1
Coelho, AL; Espindola, MS; Habiel, DM; Hogaboam, CM1

Other Studies

3 other study(ies) available for plerixafor and Cryptogenic Fibrosing Alveolitis

ArticleYear
Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration.
    Cell communication and signaling : CCS, 2023, 03-13, Volume: 21, Issue:1

    Topics: Animals; Bleomycin; Bosentan; Endothelial Cells; Epithelial-Mesenchymal Transition; Humans; Idiopathic Pulmonary Fibrosis; Lung; Matrix Metalloproteinases, Secreted; Mice; Monocytes

2023
Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes.
    Journal of controlled release : official journal of the Controlled Release Society, 2019, 11-28, Volume: 314

    Topics: Acute Lung Injury; Animals; Benzylamines; Cyclams; Disease Models, Animal; Emulsions; Heterocyclic Compounds; Idiopathic Pulmonary Fibrosis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polymers; Receptors, CXCR4; RNA, Small Interfering; Survival Rate; Tissue Distribution

2019
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.
    The American journal of pathology, 2018, Volume: 188, Issue:4

    Topics: Animals; Antibodies, Neutralizing; Benzylamines; Cyclams; Disease Models, Animal; Fibroblasts; Heterocyclic Compounds; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-13; Lung; Mice, SCID; Phenotype; Receptors, CXCR4; Receptors, Interleukin-4

2018